DISCOVERY OF CHEMICAL PROBES FOR METHYL-LYSINE READERS
DISCOVERY OF CHEMICAL PROBES FOR METHYL-LYSINE READERS
批准号:
8460807
负责人:
Stephen Vernon Frye
金额:
$27.14万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2016-01-31
关键词:
AminesAmino AcidsAnimal ModelBindingBinding ProteinsBinding SitesBiologicalBiological AssayBiologyCationsCellsChemicalsChromatinCommunitiesComplexCyclizationDNADevelopmentDevelopmental BiologyDiseaseDisease AssociationEpigenetic ProcessEventFingersGene ExpressionGene SilencingGeneticGenetic CodeGenomeGoalsHistonesHumanHuman BiologyHuman GenomeIn VitroIntellectual PropertyInterventionKnowledgeLibrariesLigandsLysineMalignant neoplasm of brainMethylationModificationMono-SNeurologyOrganismPlayPrintingProtein FamilyProteinsRNAReaderRegenerative MedicineRegulationRelative (related person)ResearchRoleScientific Advances and AccomplishmentsSeriesStructureTestingTherapeuticValidationWorkWritingbasecell typedesignepigenomegenome-widehistone modificationhuman diseasein vivo Modelinfancynoveloncologyprogramsprotein complexregenerativesmall moleculestem cell fatestereochemistrytool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Multicellular organisms have evolved elaborate mechanisms to enable differential and cell-type specific expression of genes. Epigenetics refers to these heritable changes in how DNA is accessed in different cell-types and during development and differentiation. The template upon which the epigenome is written is chromatin - the complex of histone proteins, RNA and DNA that efficiently package the genome in an appropriately accessible state within each cell. The state of chromatin, and therefore access to the genetic code, is largely regulated by specific chemical modifications to histone proteins and DNA, and the recognition of these marks by other proteins and protein complexes. Our understanding of chromatin function is in its infancy and chemical biology can play a central role in advancing scientific knowledge and assessing therapeutic opportunities. Specifically, cell penetrant, high-quality chemical probes that modulate the regulation of chromatin state are of great significance in the fields of epigenetics, oncology, developmental biology, neurology, stem cell fate and regenerative medicine. The recognition of the methylation-state of lysine residues in histones is a critical event in chromatin regulation. For example, different lysine methylation marks (KMe) are associated with active (histone 3, lysine 4 dimethylation, i.e. - H3K4Me2) and repressed transcriptional states (H3K9Me2). The more than 200 methyl-lysine binding proteins in the human genome represent a relatively unexplored set of targets for intervention with small molecules. The overarching objectives of this program are to develop pharmacological probes of methyl-lysine binding domains to pioneer both the validation of specific domains and the assay framework in which issues of selectivity and mechanism of action can be assessed. We have discovered small molecule ligands for the methyl-lysine readers, L3MBTL3 and L3MBTL1, with low micro-molar to nanomolar Kd values (ITC). Ligands for L3MBTL3 also demonstrate effects on L3MBTL3- GFP protein localization in whole cells. We propose the optimization of these series to provide high quality chemical probes. The malignant brain tumor (MBT) repeat is a structural domain of ca. 100 amino acids and occurs in 9 human proteins that recognize mono- and dimethyl-lysine modifications of histones. There are no high-quality chemical probes for MBT domains, or indeed, any other methyl-lysine binding domain. Current understanding of the biological consequences of MBT domain antagonism would suggest that antagonists may be useful in de-differentiation, re-expression of silenced genes and cellular reprogramming, We will establish a firm connection between methyl-lysine reader in vitro antagonism, cell-based localization of the targeted reader, genome-wide selectivity finger-printing and biological consequences of reader antagonism. The probes developed in the course of this research would be made freely available to the academic community with no restrictions on use or intellectual property constraints.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROBING ALLOSTERY IN METHYL-LYSINE READER DOMAINS
-
批准号:10369586
-
项目类别:
-
资助金额:$42.58万
-
财政年份:2021
-
负责人:Stephen Vernon Frye
-
依托单位:
PROBING ALLOSTERY IN METHYL-LYSINE READER DOMAINS
-
批准号:10558469
-
项目类别:
-
资助金额:$42.58万
-
财政年份:2021
-
负责人:Stephen Vernon Frye
-
依托单位:
DISCOVERY OF IN VIVO CHEMICAL PROBES FOR POLYCOMB CBX DOMAINS
-
批准号:9907857
-
项目类别:
-
资助金额:$52.06万
-
财政年份:2018
-
负责人:Stephen Vernon Frye
-
依托单位:
Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides
-
批准号:8980120
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2015
-
负责人:Stephen Vernon Frye
-
依托单位:
DISCOVERY OF CHEMICAL PROBES FOR METHYL-LYSINE READERS
-
批准号:8270684
-
项目类别:
-
资助金额:$28.12万
-
财政年份:2012
-
负责人:Stephen Vernon Frye
-
依托单位:
Discovery of Small Molecule MBT Domain Antagonists
-
批准号:7943037
-
项目类别:
-
资助金额:$44.16万
-
财政年份:2009
-
负责人:Stephen Vernon Frye
-
依托单位:
Discovery of Small Molecule MBT Domain Antagonists
-
批准号:7812717
-
项目类别:
-
资助金额:$43.42万
-
财政年份:2009
-
负责人:Stephen Vernon Frye
-
依托单位:
Molecular Therapeutics Research Program
-
批准号:10089813
-
项目类别:
-
资助金额:$4.51万
-
财政年份:1997
-
负责人:Stephen Vernon Frye
-
依托单位:
Molecular Therapeutics Research Program
-
批准号:10534183
-
项目类别:
-
资助金额:$4.51万
-
财政年份:1997
-
负责人:Stephen Vernon Frye
-
依托单位:
Molecular Therapeutics Research Program
-
批准号:10320874
-
项目类别:
-
资助金额:$4.51万
-
财政年份:1997
-
负责人:Stephen Vernon Frye
-
依托单位:
海外基金